Cancer will have no place to hide...
Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies.
Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.
Company Details
- Employees
- 18
- Founded
- 2009
- Address
- 6-16 Joseph Street, Blackburn North,victoria 3130,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- affinitybio.com.au
- HQ
- Blackburn North, Victoria
Myrio Tx Questions
Myrio Tx's website is affinitybio.com.au
Myrio Tx's LinkedIn profile is https://au.linkedin.com/company/myriotx
Myrio Tx has
18 employees.
View email and phone details for 18
employees at Myrio Tx.
Myrio Tx's industry is
Biotechnology Research
Myrio Tx's top competitors are
Noxopharm Limited,
Rhythm Biosciences Limited,
Ternarx,
Imugene Limited,
Audax Biosciences,
Prescient Therapeutics,
Carina Biotech,
Crux Biolabs,
Aucentra Therapeutics,
Psaio Tx.
Myrio Tx's categories are Biotechnology Research
Myrio Tx's founding year is 2009
